来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

AED
现在位置首页>实验室原料试剂耗材>中间体>中间体>S2187 Avasimibe(CI-1011)现货
S2187 Avasimibe(CI-1011)现货
S2187 Avasimibe(CI-1011)现货
  • S2187 Avasimibe(CI-1011)现货

S2187 Avasimibe(CI-1011)现货

产品报价:询价

更新时间:2012/7/18 17:15:48

地:北京

牌:selleck

号:S2187

厂商性质: 生产型,贸易型,服务型,

公司名称: 北京乐博生物科技有限公司

产品关键词:

303
访问人数
0
累计评论


刘小姐 : (13621283223) (4006130504)

(联系我时,请说明是在来宝网上看到的,谢谢!)


 

该产品另有其他规格及报价,欢迎来电垂询。
Technical Data:
M.Wt: 501.72
Formula: C29H43NO4S
Solubility: Unknown
Purity: >99%
Storage: at -20℃ 2 years
CAS No.: 166518-60-1
 

北京乐博生物科技有限公司代理供应美国Selleck chem公司全线产品。 

Biological Activity of Avasimibe(CI-1011):

 

Avasimibe(CI-1011) is a novel orally bioavailable acyl coenzyme A:cholesterol acyltransferase inhibitor with IC50 of 2.9, 13.9, 26.5 µM for CYP2C9, CYP1A2, and CYP2C19.
Avasimibe(CI-1011) has been previously shown to be a potent inducer of CYP3A4 and multiple drug resistance protein 1. [1] In a study, avasimibe decreased the VLDL apoB pool size by 40–43% and the hepatic secretion rate of VLDL apoB by 38–41%, but did not alter its fractional catabolism. Avasimibe decreased the LDL apoB pool size by 13–57%, largely due to a dose-dependent 25–63% in the LDL apoB production rate. Hepatic LDL receptor mRNA abundances were unchanged, consistent with a marginal decrease in LDL apoB FCRs. Hepatic ACAT activity was decreased by 51% (P = 0.050) and 68% (P = 0.087) by low and high dose avasimibe, respectively. [2][3]